Syros Pharmaceuticals focuses on understanding and manipulating gene expression to develop innovative therapies for cancer and other diseases. The company has developed a gene control platform that allows for the exploration of regulatory regions of the genome, which are crucial in determining how genes are expressed. By identifying and targeting these regulatory elements, Syros aims to create small molecule drugs that can effectively address cancers that have been resistant to traditional genomics-based approaches. This platform represents a significant advancement in drug discovery, as it enables the investigation of previously underutilized areas of the genome.

The company's research has led to the identification of specific targets for drug development, particularly in the context of myelodysplastic syndromes and other hematological malignancies. For instance, their recent clinical trial, SELECT-MDS-1, focuses on the use of Tamibarotene in patients with higher-risk myelodysplastic syndrome characterized by RARA gene overexpression. This highlights Syros' commitment to leveraging its gene control technology to develop targeted therapies that can improve patient outcomes in complex diseases where conventional treatments may fall short.

United States

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline, including SY-1425, a first-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in a Phase 1 trial in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Cancer

Hematologic Diseases

Syros Pharmaceuticals

Acute myeloid leukemia

SY-1425 is an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist that is currently in a Phase 2 clinical trial to assess its efficacy and safety in combination with azacitidine, a standard-of-care therapy, in genomically defined subsets of AML patients, including those with relapsed or refractory (r/r) AML.

Tamibarotene (SY-1425) (RARα agonist) in combination with venetoclax and azacitidin

Prostate cancer

Prostate disease

SM-88 is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events.

SM-88

Myelodysplastic syndrome

Tamibarotene (SY-1425) (RARα agonist)

COVID-19

TYME-19 is an oral synthetic bile acid that has demonstrated broad spectrum antiviral activity as well as efficacy against COVID-19 in preclinical studies

TYME-19

Bone cancer

Sarcoma

SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events.

Breast cancer

SM-88 

SY-2101 is a novel oral form of arsenic trioxide (ATO) that we are developing for acute promyelocytic leukemia (APL), a &nbsp;subtype of acute myeloid leukemia (AML) that is caused by a fusion of the RARA and PML genes.
 
Source: <a href="https://www.syros.com/programs/sy-2101">https://www.syros.com/programs/sy-2101</a>

SY-2101: Oral arsenic trioxide (ATO) 

SY-5609 is a highly selective and potent oral inhibitor of the cyclin-dependent kinase 7 (CDK7) in a Phase 1 dose-escalation trial in patients with advanced breast, colorectal, lung, ovarian or pancreatic cancer, or with solid tumors of any histology that harbor Rb pathway alterations.
 
SY-5609 represents a new approach to treating cancer that we believe has potential in a range of difficult-to-treat cancers. It has shown robust anti-tumor activity, including complete regressions, in preclinical models of breast, colorectal, lung and ovarian cancers at doses below the maximum tolerated dose. In preclinical studies of breast, lung and ovarian cancers, deeper and more sustained responses were associated with the presence of Rb pathway alterations. SY-5609 has also shown substantial anti-tumor activity in combination with fulvestrant in treatment-resistant models of estrogen receptor-positive breast cancer, including those resistant to both fulvestrant and a CDK4/6 inhibitor. Early dose-escalation data demonstrated proof-of-mechanism at tolerable doses.
 
Source: <a href="https://www.syros.com/programs/sy-5609">https://www.syros.com/programs/sy-5609</a>

Syros Pharmaceuticals

Company Details